Toolkit for Nucleosome & Histone Research
AMSBIO has announced addition of new biotinylated histones and nucleosomes to its expanding range of recombinant nucleosomes, purified nucleosomes and full length histone proteins.
A nucleosome is the basic unit of DNA packaging. It consists of a segment of DNA wound around a core ('octamer') of eight histone proteins (two each of histones H2A, H2B, H3, and H4). The 'tails' of these histone proteins stick out, where they can be modified by a number of different histone acetyltransferases, methyltransferases, PARPs, and other epigenetic enzymes. Many of these enzymes modify very specific sites; for example, EZH2, specifically tri-methylates the lysine at position 27 in the H3 histone.
AMSBIO's new line of biotinylated histone peptides have been developed for enzyme kinetic studies, as well as for screening small molecular inhibitors of different histone methyltransferases in drug discovery and HTS applications.
The major difference between AMSBIO recombinant nucleosomes made in E. coli and those purified from whole cells is that the recombinant ones are unmodified. E. coli and other bacteria do not have the enzymes to methylate or acetylate the histone proteins. AMSBIO nucleosomes purified from mammalian cells are supplied methylated or acetylated on most histone sites, making them suitable substrates for demethylases.
For further information on the complete range of nucleosomes and histones available from AMSBIO please visit www.amsbio.com/Nucleosomes-and-Histone-Proteins.aspx
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...